123 results about "Intestinal bacteria" patented technology

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention relates to the technical field of food nutrition and health care and biological medicines, in particular to application of beta-1, 3 / alpha-1, 3-glucan in preparation of medicines for treating and / or preventing obesity and / or body weight super-severe illness and digestion-aiding health food. According to the experimental results, high-glucose and high-fat rats are continuously fed in the stomach for 8 weeks, and the food intake can be effectively reduced and the body weight can be reduced through preventive administration; the conclusion that beta-1, 3 / alpha-1, 3-glucan has the digestion-aiding health-care food function can be obtained according to the requirements of'health-care food function inspection and evaluation method (2023 edition) by combining the research results that beta-1, 3 / alpha-1, 3-glucan has the stimulation effect on small intestine peristalsis, promotes the growth of intestinal beneficial bacteria and regulates intestinal health in the existing research. The invention provides a new direction for preparing the medicine for treating and / or preventing obesity and / or body weight super-severe illness and health-care food beneficial to digestion.

The invention belongs to the field of biological medicine, and particularly relates to bifidobacterium bifidum and application of the bifidobacterium bifidum in eye health products, and the bifidobacterium bifidum BB00 has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.34389. The invention further discloses a preparation method of the bifidobacterium bifidum. The bifidobacterium bifidum BB00 can improve clinical symptoms of xerophthalmia, increase tear secretion amount, prolong tear film rupture time, reduce ocular surface disease indexes, relieve corneal epithelium injury, adjust the opening degree of palpebral fissure, adjust intestinal flora composition, improve flora diversity and inhibit growth of intestinal pathogenic bacteria. The bifidobacterium bifidum BB00 not only provides an innovative solution for a clinical pain point of xerophthalmia and realizes synergistic intervention of intestinal regulation and eye health, but also has scientific innovation, clinical effectiveness and industrialization potential, and has important value for application of bacteria and fungicide in the field of biological medicine and treatment of ocular surface-intestinal tract related diseases.

The present invention belongs to the field of biotechnology and pharmaceutical engineering technology, and discloses a functionalized drug-loaded exosome based on milk exosomes, a preparation method thereof, and an application thereof. The functionalized drug-loaded exosomes include a carrier and a water-insoluble drug, and the water-insoluble drug is loaded inside the carrier; wherein the surface of the carrier is loaded with milk exosomes with functionalized molecules, and the functionalized molecule is any one of phosphatidylserine, a molecule capable of macrophage targeting, and a molecule or polymer that enhances the targeting and stability of milk exosomes; the water-insoluble drug is any one of an antibacterial drug, an antitumor drug, and a gene drug. The functionalized drug-loaded exosomes in the present invention can improve the gastrointestinal stability of oral administration and enhance the efficacy against bacterial pathogens; expand the application scope of milk exosomes in the fields of anti-intestinal bacterial infection and food preservation, and the exosome content in milk is very rich, which is convenient for large-scale preparation and has important application value.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The present invention relates to a composition for alleviating obesity, improving cognitive function and memory, and preventing Alzheimer's disease, comprising a fermented hemp seed product as an active ingredient. The fermented hemp seed product prepared by inoculating a Pediococcus acidilactici OHSI1 strain (deposit number: KCTC 15831BP) strain, of the present invention, has the effects of: increasing the abundance and diversity of intestinal microorganisms; increasing beneficial intestinal bacteria; reducing harmful intestinal bacteria; alleviating intestinal microbial flora imbalance; anti-obesity; antioxidation; and controlling Alzheimer's disease-associated enzyme activity, and thus can be effectively used as a food composition or a pharmaceutical composition for preventing, alleviating, or treating obesity or cognitive dysfunction, and as a health functional food composition for improving memory and cognitive function by improving intestinal microbial flora.

The invention relates to a gastric acid-resistant sustained-release intestinal bacteria capsule based on bionic mucous membrane-enzymolysis response and a preparation method thereof. The gastric acid-resistant sustained-release intestinal bacteria capsule comprises a core layer, an adhesive layer, an outer-layer composite film and a protective coating from inside to outside, the core layer consists of intestinal flora and a multifunctional freeze-drying protective agent; the adhesive layer is composed of trehalose, N-acetyl glucosamine and MUC2 recombinant protein; the outer-layer composite film is composed of a base material and a functional filler; the protective coating is composed of beewax and chitosan. The anti-gastric acid sustained-release intestinal bacteria capsule based on bionic mucosa-enzymolysis response provided by the invention has excellent gastric acid resistance, and the gastric acid resistance is remarkably improved; good slow release performance is achieved, and accurate slow release of enzymatic hydrolysis response can be achieved; the colonization efficiency of the intestinal bacteria can be effectively improved; the storage stability is good. The preparation method provided by the invention has the advantages of simplified steps, short time consumption, controllable core operation time and obviously shortened whole process, and is beneficial to keeping the activity of the flora.

The invention discloses a method for separating and detecting new intestinal bacterial exovesicles, which comprises the following steps: (1) carrying out metabolism labeling on microorganisms to be researched by an azido-modified hydrochloric acid D-type amino acid metabolism marker, so that the new intestinal bacterial exovesicles carry azido groups; (2) separating and extracting the bacterial exovesicles from a sample containing the bacterial exovesicles; (3) adding a capture connector capable of reacting with an azide group into the extracted bacterial outer vesicles; and (4) separating, capturing and detecting the bacterial outer vesicles obtained in the step (3) by adopting a micro-fluidic chip, wherein the obtained bacterial outer vesicles are newborn bacterial outer vesicles. The method disclosed by the invention can selectively capture the newborn bacterial exovesicles from the sample under the condition of not influencing surface protein expression of the bacterial exovesicles so as to carry out downstream analysis on the newborn bacterial exovesicles of the intestinal flora.

The invention relates to the technical field of comprehensive treatment of agricultural pests, and particularly provides a bactrocera cucurbitae double-trapping type attractant based on optimal matching of host and intestinal bacteria volatile matters and application of the bactrocera cucurbitae double-trapping type attractant. The attractant comprises an active component and a synergistic component, the active component is derived from balsam pear and towel gourd volatile matters and bactrocera cucurbitae intestinal bacterial metabolites, and comprises 2-methyl ethyl valerate, propyl hexanoate, ethyl hexadienoate, heptanal, benzyl alcohol, 3-methyl acetic acid-1-butanol, indole and 1-undecanol; and the synergistic component is myzobenzoic ketone. Active components are quickly released in the early stage of application, so that the attraction efficiency is remarkably improved; the synergistic component prolongs the trapping lasting period through the slow release effect, and the long-term trapping effect is ensured. All the components of the attractant provided by the invention are biological sources or environment-friendly chemical substances, the attractant meets the requirement of green prevention and control, can efficiently attract male and female adults at the same time, makes up the limitation that a traditional sex attractant only induces male adults or a food attractant only induces female adults, and is beneficial to more comprehensive control of population quantity.

The application discloses a hybridoma cell strain 6F92E10, a monoclonal antibody thereof and application thereof, and belongs to the technical field of biotechnology.The application provides a hybridoma cell strain secreting an anti-mucinophilic Akkermansia monoclonal antibody.The antibody secreted by the hybridoma cell strain only combines with AKKermansia and does not cross-react with other common intestinal bacteria.In addition, the application solves how to detect the adhesion and colonization of mucinophilic Akkermansia in the colon of a mouse by using the prepared monoclonal antibody through an indirect immunofluorescence localization experiment, and expands the application range of the antibody.

The utility model relates to the technical field of culture medium shunting, in particular to an intestinal bacterium enrichment liquid culture medium self-flowing racking machine which is characterized in that when the racking machine is used, a plurality of groups of culture bottles are respectively placed on a bottle carrying assembly, and then the bottle carrying assembly is placed on a supporting table and is positioned and fixed through two groups of positioning assemblies; then liquid adding operation is conducted on the multiple sets of culture bottles through the flow dividing assembly, after liquid adding is completed, a worker integrally moves the multiple sets of culture bottles through the bottle carrying assembly, then the other set of bottle carrying assembly is placed and positioned, and the liquid adding efficiency is improved; comprising a supporting table, supporting legs and a liquid storage tank, the multiple sets of supporting legs are arranged at the bottom end of the supporting table, the liquid storage tank is installed at the top end of the supporting table, the distribution assembly is arranged at the output end of the liquid storage tank, the bottle carrying assembly is used for transferring multiple sets of culture bottles, and the two sets of positioning assemblies are symmetrically arranged at the top end of the supporting table.

To provide: a technique that can predict the prognosis of inflammatory bowel disease, can contribute to verifying treatment effects at that point in time, imposes less physical burden, and has high accuracy (low likelihood of missing individuals at risk of worsening disease); and a technique that can contribute to diagnosing inflammatory bowel disease, imposes less physical burden, and enables inexpensive and rapid testing of the likelihood of contracting inflammatory bowel disease.SOLUTION: A method for predicting the prognosis of inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject. A method for testing inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject.SELECTED DRAWING: Figure 6

This invention provides a multi-omics diagnostic model for inflammatory bowel disease (IBD), along with its biomarker screening method, applications, and reagent kits. Currently, there is no gold standard for diagnosing IBD, leading to many unidentifiable suspected cases in clinical practice. This invention utilizes information on the abundance of gut bacteria, the functional genes of gut bacteria, and the content of intestinal metabolites to establish a predictive model for IBD. Furthermore, this invention integrates the above two types of omics information and the prediction across three information dimensions to establish a predictive model with impressive predictive capabilities. The method and model of this invention can assist in the diagnosis and differentiation of IBD.

The invention discloses bactrocera cucurbitae intestinal bacterium compound bacteria and application thereof, and relates to the technical field of biology. The bacterial compound bacteria comprise the providencia rettgeri M15 and the providencia mantanoxydans M52, the preservation number of the providencia rettgeri M15 is CGMCC (China General Microbiological Culture Collection Center) 1.62474, and the preservation number of the providencia mantanoxydans M52 is CGMCC 1.62475. The invention further discloses a preparation method of the bacterial compound bacteria, and the bacterial compound bacteria comprise the providencia rettgeri M15 and the providencia mantanoxydans M52. The compound bacteria are mainly used for improving the survival rate of bactrocera cucurbitae larvae.

A toilet system according to an embodiment of the present invention comprises: a first detection sensor that is provided to a toilet device and detects odorless gas; a second detection sensor that is provided to the toilet device and detects odorous gas; and an estimation means for estimating, on the basis of detection results from the first detection sensor and the second detection sensor, at least one of the intestinal bacteria, metabolites of intestinal bacteria, or pH of a user who uses the toilet device.

The invention relates to the technical field of coprophilous fungus transplantation, in particular to an intestinal fungus capsule and a preparation process thereof. The preparation process comprises the following steps: preparing the fecal fungi; adding a special freeze-drying protective agent and then carrying out freeze-drying treatment; and filling the freeze-dried bacterial powder into a capsule to prepare the intestinal bacterial capsule. The freeze-drying protective agent comprises the following raw materials: cane sugar, whey protein, mannitol, trehalose, lecithin, vitamin C and water. By optimizing a freeze-drying protective agent formula and an accurate freeze-drying process, the freeze-drying survival rate of thalli is remarkably improved, and a test result shows that the survival rate of probiotics such as bifidobacterium and lactic acid bacteria exceeds 90%. The capsule form is adopted to ensure that thalli are accurately released in the intestinal tract, discomfort and thalli loss caused by a traditional transplantation mode are avoided, and the storage stability is effectively improved.

The present invention provides a donor-recipient matching model for enterobacteria transplantation and a method for constructing the same. By combining donor and recipient information, the donor-recipient matching model is successfully constructed through metagenomic sequencing, meta-analysis, and neural network modeling. The model is applied to clinical experiments for performance comparison and evaluation of the reliability of the model, verifying the feasibility of the model prepared by the present invention and can be successfully applied to the treatment of gynecological diseases.

The invention relates to the technical field of biological medicines, in particular to application of intestinal probiotics and metabolites thereof in treating autism spectrum disorders. According to the application disclosed by the invention, six intestinal bacteria which are in causal negative correlation with ASD are identified for the first time from the perspective of genetics, and the effects of ruminococcus gavreuii of the ruminococcus and the effects of Satasella wadsworensis of the ruminococcus on the autism spectrum disorder are verified. The invention also discloses a kit for detecting the autism spectrum disorder of the Autism spectrum disorder and a kit for detecting the autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder. Experiments prove that the traditional Chinese medicine composition can significantly improve social defects of model mice and has no side effects on normal mice. The invention provides new targets and candidate substances for developing probiotic preparations, metabolite supplements or functional foods for preventing, relieving or treating ASD, and has important clinical application prospects.

This invention discloses a method for the synergistic metabolic analysis of multiple components of traditional Chinese medicine (TCM) integrated with the gut microbiota. After initializing the microbiota ecosystem, a solution of multi-component TCM extracts is continuously injected into a microfluidic chip. Stable isotope-labeled precursors are pulsed into a specific simulation region to perform spatial isotope encoding. A standing wave acoustic field is applied at the sampling node of the microfluidic chip, and multiphase fluid spatial splitting is performed using the difference in the primary acoustic radiation force experienced by the particles to derive cell-free TCM metabolites. The cell-free TCM metabolites are separated by chromatography and gas phase drift separation. A four-dimensional metabolic feature array is constructed, and the absolute value of the mass shift is calculated for spatial inverse decoding. Closed-loop feedback is triggered based on the rate of change of target metabolite ion abundance, increasing the amplitude of the standing wave acoustic field pressure to confine intestinal bacteria and performing in-situ enrichment of synergistic metabolic intermediates. This invention realizes the spatial metabolic trajectory tracing and network reconstruction of multiple components of TCM in a complex gut microbiota ecosystem.

A use of intestinal bacteria that co-produce D-lactate and a metabolite thereof D-lactate in predicting exercise capacity. The intestinal bacteria that co-produce D-lactate and the metabolite thereof D-lactate affect the levels of the exercise-related hormones dopamine and adrenaline, thereby significantly impairing exercise capacity. The intestinal bacteria that co-produce D-lactate and the metabolite thereof D-lactate are markers that can be used for routine exercise monitoring and for regulating exercise tolerance.

The present invention addresses the problem of: developing a method capable of noninvasively sampling and analyzing intestinal mucosa bacteria; analyzing the intestinal bacteria, especially intestinal mucosa bacteria on the basis of the method; and developing a therapeutic method for diseases occurring in the intestinal tract for which therapeutic methods have not been established.　The inventors of the present invention have found that bacteria contained in a cotton swab (swab) sample on the feces surface exhibit a bacterial flora composition similar to that of bacteria existing in the intestinal mucosa; and, as a result of analysis based on the finding, have clarified that Adlercreutzia, which has not been reported until now as a mucosa-related bacterium, lives in the large intestinal mucosa layer, produces taurine, which is a strong anti-inflammatory compound, by the action of the bile acid-deconjugating enzyme, and alleviates enteritis, thereby completing the present invention. In other words, the present invention can provide a composition having an anti-inflammatory effect, which includes a bacterium of the genus Adlercreutzia, or a bile acid-deconjugating enzyme that is derived from a bacterium of the genus Adlercreutzia.

The invention belongs to the technical field of bioengineering, and discloses a specific identification primer and method for lactobacillus curvatus in human intestinal tracts and application. The identification primer comprises an upstream primer COG3825F1 and a downstream primer COG3825R1, the nucleotide sequence of the upstream primer COG3825F1 is 5 '-GTCACAACAAGACCGATTT-3', and the nucleotide sequence of the downstream primer COG3825R1 is 5 '-CTGTTTCTACAACTTGTGCT-3', and the nucleotide sequence of the upstream primer COG3825F1 and the nucleotide sequence of the downstream primer COG3825R1 are 5 '-GTCACAACAAGACCGATTT-3'. The specific COG3825 gene of the lactobacillus flexus is screened to serve as a target sequence design primer, and PCR, gel electrophoresis and qPCR verification show that the primer has extremely high specificity and sensitivity and can accurately distinguish the lactobacillus flexus from the related lactobacillus and other common intestinal bacteria under the complex micro-ecological background of the human intestinal tract; the identification method based on the primer is easy and convenient to operate and accurate in result, qualitative and quantitative detection of the lactobacillus brevis in human intestinal samples, food samples and other environment samples can be achieved, and important technical support is provided for related research, application development and micro-ecological monitoring of the lactobacillus brevis.

The invention discloses a glycosyl hydrolase derived from intestinal bacteria and application of the glycosyl hydrolase. A glycosyl hydrolase gene for catalyzing trillioside to be hydrolyzed into diosgenin is cloned from intestinal microorganism enterococcus faecalis for the first time, and protein coded by the glycosyl hydrolase gene is identified as multifunctional glycosyl hydrolase; the diosgenin can be catalyzed to generate diosgenin, and the hydrolysis of other saponins such as steroid saponin and C3, C6 and C21 glycosyl of ginsenoside can be catalyzed, so that a basis is provided for the biological enzymolysis of the diosgenin and other saponins or sapogenin. Meanwhile, biological enzymolysis of the diosgenin makes up for the defects of high production cost, serious environmental pollution and the like of a traditional acid hydrolysis method, and the diosgenin has a great application prospect.

The invention relates to the technical field of biomedicine, and discloses application of bacteroides sailli as a biomarker in preparation of sepsis diagnosis and / or prognosis evaluation products. The kit for the auxiliary diagnosis of the sepsis comprises a reagent for detecting the bacteroides sailli (Bacteroides sailli), and the reagent is used for detecting the bacteroides sailli (Bacteroides sailli). As a detection variable of sepsis, the single bacterium of Bacteroides sailli has high specificity and sensitivity, can be applied to diagnosis of sepsis patients as a detection marker, is high in accuracy, provides an intestinal flora detection means for the sepsis patients, provides a bacterium source basis for judging sepsis and intestinal flora disorder of the patients according to the intestinal flora detection means, and has a good application prospect. And a basis is provided for later-stage intestinal bacteria transplantation.

The invention discloses application of chlorogenic acid in preparation of a product with functions of protecting intestinal mucosa and regulating intestinal flora, and belongs to the technical field of medical health care products. Animal experiments prove that the chlorogenic acid can effectively relieve intestinal mucosa barrier damage caused by hypoxia, reverse abnormal increase of alpha-diversity of intestinal bacteria and optimize the flora structure in allusion to the fact that the regulation effect of the chlorogenic acid on the intestinal mucosa damage and intestinal flora disorder induced by hypoxia is not involved in the prior art. The product is suitable for preventing and treating intestinal mucosal barrier damage and intestinal microecological imbalance caused by acute and chronic hypoxia or drug stimulation.

The application belongs to the technical field of microorganisms, and provides a carogenic Enterobacter and application thereof in degrading solanum alkaloid. Enterobacter cancerogenus JLU1, which was preserved in the China General Microbiological Culture Collection Center on June 23, 2025, and has a preservation number of CGMCC No.34971. In the embodiment of the application, intestinal bacteria are separated by dissecting the tomato leafworm larva intestine, and then bacteria resistant to solanum alkaloid or even capable of degrading and utilizing solanum alkaloid are screened and identified, so that the role of the bacteria in the resistance of the tomato leafworm to solanum alkaloid is analyzed, and a foundation is laid for subsequent research on the resistance mechanism.

The invention discloses an intestinal bacterium-derived melatonin synthetase and an application thereof. Specifically, the melatonin synthetase is selected from one or more of a DDC enzyme, an AANAT enzyme and an AST enzyme, the DDC enzyme comprises an amino acid sequence as shown in SEQ ID NO.2 or an active fragment of the amino acid sequence, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.2 is more than 80%, and the DDC enzyme comprises an amino acid sequence as shown in SEQ ID NO.2 or an active fragment of the amino acid sequence as shown in SEQ ID NO.2 or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.2 is more than 80%. The AANAT enzyme comprises an amino acid sequence as shown in SEQ ID NO.34 or an active fragment thereof, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.34 is more than 80%, and the AST enzyme comprises an amino acid sequence as shown in SEQ ID NO.42 or an active fragment thereof, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.42 is more than 80%. On one hand, the melatonin synthetase can be used for improving the melatonin level of a host and improving related diseases; on the other hand, the method can be used for biosynthesis of melatonin and has a good application prospect.

The invention is applicable to the technical field of microorganisms, and provides enterobacter cancerogenus and application of the enterobacter cancerogenus to degradation of tomaquine, the enterobacter cancerogenus is an enterobacter cancerogenus JLU1 strain and is preserved in the China General Microbiological Culture Collection Center on June 23, 2025, and the preservation number is CGMCC No.34971. The enterobacter cancerogenus JLU1 has the advantages that the enterobacter cancerogenus JLU1 can be used for degrading tomaquine, and the enterobacter cancerogenus JLU1 can be used for degrading tomaquine; according to the embodiment of the invention, the intestinal bacteria are separated by dissecting the intestinal tract of the tomato leaf miner larva, so that the bacteria which have resistance to the tomatidine and even can degrade and utilize the tomatidine are screened, and the effect of the bacteria in the resistance of the tomato leaf miner to the tomatidine is identified and analyzed, and a foundation is laid for subsequent research on analysis of a resistance mechanism.

This anti-obesity agent is characterized by containing L. plantarum or the membrane vesicle (MV) thereof as an active ingredient.

Provided in the present invention is an engineered bacterium, the engineered bacterium comprising an exogenous cyuP gene and / or cyuA gene, the exogenous cyuP gene encoding a cysteine transporter protein, the exogenous cyuA gene encoding a cysteine desulfurase, and the engineered bacterium being an intestinal bacterium or a probiotic.